Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
REFINE
A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis
- NCT03222609 ↗
- Completed
- AbbVie
- Focused
We haven't built an HCP commentary report on REFINE yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on REFINE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Myelofibrosis (MF)
- Interventions
- Ruxolitinib; Navitoclax
- Arms
- Navitoclax + ruxolitinib (Cohort 1a) · Experimental
- Navitoclax + ruxolitinib (Cohort 1b) · Experimental
- Navitoclax (Cohort 2) · Experimental
- Navitoclax + ruxolitinib (Cohort 3) · Experimental
- Enrollment
- 191
- Primary outcomes
- Percentage of Participants With ≥ 35% Reduction From Baseline in Spleen Volume at Week 24
- Sponsor
- AbbVie
- Start
- Oct 31, 2017
- Primary completion
- Mar 28, 2022
- Results posted
- Yes
- Registry record
- NCT03222609 · updated Jan 20, 2026
Publications
linked from the registry- Rampal RK, Harrison CN, Mesa R, Vannucchi AM, Shimoda K, Perkins A, Garcia JS, Reiter A, Radinoff A, Pane F, Palandri F, Lomaia E, Lee SE, Chuah HS, Passamonti F, Saydam G, Turgut M, Yoon SS, Bain EE, Lam H, Jain S, Potluri J, Kiladjian JJ. Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies. Leuk Lymphoma. 2026 Oct 7:1-11. doi: 10.1080/10428194.2026.2739358. Online ahead of print. PubMed 42842696
- Passamonti F, Foran JM, Tandra A, De Stefano V, Fox ML, Mattour A, McMullin MF, Perkins AC, Rodriguez-Macias G, Sibai HA, Polepally AR, Sun Y, Chopra AS, Harb JG, Qin Q, Potluri J, How J. Preliminary Safety and Efficacy of Navitoclax Plus Ruxolitinib in Janus Kinase Inhibitor-Naive Patients With Myelofibrosis From the Multicenter, Open-Label, Phase 2 Study (REFINE). Hematol Oncol. 2026 Mar;44(2):e70180. doi: 10.1002/hon.70180. PubMed 41846295
- Pemmaraju N, Somervaille TCP, Palandri F, Harrison C, Komrokji RS, Perkins A, Ayala Diaz RM, Lavie D, Tomita A, Feng Y, Qin Q, Harb J, Polepally AR, Potluri J, Garcia JS. Addition of navitoclax to ruxolitinib for patients with myelofibrosis with progression or suboptimal response. Blood Neoplasia. 2024 Nov 2;2(1):100056. doi: 10.1016/j.bneo.2024.100056. eCollection 2025 Feb. PubMed 40454409
- Pemmaraju N, Garcia JS, Potluri J, Harb JG, Sun Y, Jung P, Qin QQ, Tantravahi SK, Verstovsek S, Harrison C. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study. Lancet Haematol. 2022 Jun;9(6):e434-e444. doi: 10.1016/S2352-3026(22)00116-8. Epub 2022 May 13. PubMed 35576960
- Harrison CN, Garcia JS, Somervaille TCP, Foran JM, Verstovsek S, Jamieson C, Mesa R, Ritchie EK, Tantravahi SK, Vachhani P, O'Connell CL, Komrokji RS, Harb J, Hutti JE, Holes L, Masud AA, Nuthalapati S, Potluri J, Pemmaraju N. Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy. J Clin Oncol. 2022 May 20;40(15):1671-1680. doi: 10.1200/JCO.21.02188. Epub 2022 Feb 18. PubMed 35180010